Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Biogen Inc. has bolstered its immunology research efforts by acquiring RayThera Inc., adding several promising assets to its pipeline, including a lead candidate set to begin Phase 1 clinical trials. This strategic move underscores Biogen’s commitment to expanding its therapeutic options in immunology, a field with significant potential for addressing autoimmune and inflammatory diseases. With this acquisition, Biogen aims to enhance its competitive edge in developing innovative treatments for these conditions, potentially offering new hope to patients worldwide.